tiprankstipranks
Trending News
More News >

Pharma Mar’s Zepzelca® Gains Approval in Argentina for SCLC Treatment

Story Highlights
  • Pharma Mar SA received approval in Argentina for Zepzelca® to treat metastatic SCLC.
  • The approval expands lurbinectedin’s availability to 18 territories, enhancing its market impact.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Pharma Mar’s Zepzelca® Gains Approval in Argentina for SCLC Treatment

Confident Investing Starts Here:

Pharma Mar SA ( (ES:PHM) ) has issued an update.

Pharma Mar SA, in partnership with Adium Pharma SA, has received conditional marketing approval in Argentina for Zepzelca® (lurbinectedin) to treat metastatic small cell lung cancer (SCLC) in adults. This approval, based on clinical trial data, expands the availability of lurbinectedin to 18 territories globally, highlighting its growing impact in cancer treatment markets, particularly in Latin America.

The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.

More about Pharma Mar SA

Pharma Mar SA is a biotechnology company focused on the development and commercialization of innovative drugs, primarily targeting cancer treatment. The company is known for its marine-derived drugs and has a significant market presence in oncology.

YTD Price Performance: -1.63%

Average Trading Volume: 59,625

Technical Sentiment Signal: Buy

Current Market Cap: €1.41B

See more data about PHM stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App